Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: A phase 2 trial

By Abou-Jawde Rony   Reed Janice   Kelly Megan   Walker Esteban   Andresen Steven   Baz Rachid   Karam Mary   Hussein Mohamad  

Medical Oncology, Vol. 23, Iss. 2, 2006-06 ,pp. : 263-272

Humana Press, Inc

Access to resources Recommend Favorite

Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways

By        

Oncology Reports, Vol. 28, Iss. 5, 2012-01 ,pp. : 1851-1858

Spandidos Publications

Access to resources Recommend Favorite

A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma

By Held Lauren A.   Rizzieri David   Long Gwynn D.   Gockerman Jon P.   Diehl Louis F.   Castro Carlos M. de   Moore Joseph O.   Horwitz Mitchell E.   Chao Nelson J.   Gasparetto Cristina  

Cancer Investigation, Vol. 31, Iss. 3, 2013-03 ,pp. : 172-176

Informa Healthcare

Access to resources Recommend Favorite

Arsenic Trioxide and Breast Cancer: Analysis of the Apoptotic, Differentiative and Immunomodulatory Effects

By Baj G.  

Breast Cancer Research and Treatment, Vol. 73, Iss. 1, 2002-05 ,pp. : 61-73

Springer Publishing Company

Access to resources Recommend Favorite

Treatment of Multiple Myeloma: Current Management and New Approaches

By Ho P.J.   Gibson J.   Joshua D.E.  

American Journal of Cancer, Vol. 3, Iss. 1, 2004-01 ,pp. : 47-66

Adis International

Access to resources Recommend Favorite